NCT06964009View on ClinicalTrials.gov

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Ovarian CancerOvarian CarcinomaRecurrent Ovary CancerRecurrent Platinum-Resistant Ovarian Carcinoma
Interventions
DRUG

DT2216

A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.

DRUG

Paclitaxel

An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.

Trial Locations (2)

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Dialectic Therapeutics, Inc

INDUSTRY

collaborator

American Society of Clinical Oncology

OTHER

lead

Elizabeth Stover, MD, PhD

OTHER